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Purpose: Cynarin, a potential immunosuppressant that blocks the interaction between the CD28 of T-cell
receptor and CD80 of antigen presenting cells, was found in Echinacea purpurea by a new
pharmaceutical screening method: After Flowing Through Immobilized Receptor (AFTIR; Dong et al.,
J Med Chem, 49: 1845-1854, 2006). This Echinacea component is the first small molecule that is able to
specifically block “signal 2” of T-cell activation.
Methods: In this study, we used the AFTIR method to further confirm that cynarin effectively blocked
the binding between CD80 of B-cells and CD28 of T-cells, and provide details of its mechanism of action.
Results: The experimental results showed that cynarin blocked about 87% of the CD28-dependent
“signal 2” pathway of T-cell activation under the condition of one to one ratio of T-cell and B-cell in vitro.
Theoretical structure modeling showed that cynarin binds to the “G-pocket” of CD28 (Evans et al., Nat
Immunol, 6:271-279, 2005), and thus interrupts the site of interaction between CD28 and CD80.
Conclusions: These results confirm both that AFTIR is a promising method for screening selective active
compounds from herbal medicine and that cynarin has great potential as an immuno-suppressive agent.
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INTRODUCTION
Resting T-cells are stimulated to initiate immune activity
in response to specific external stimuli, such as by the
approach of antigen-presenting cells (APCs). After making
contact with an APC, resting T-cells are activated via the so-
called “signal 1” and “signal 2” pathways (1–3). The “signal
1” pathway is initiated by a binding interaction between
surface-presented antigen and the major histocompatibility
complex (MHC) present on the cell surface of APC cells, and
the T-cell receptor (TCR) of T-cells. Signal 1 only induces a
partial T-cell response. In addition, there is a second signal,
“signal 2”, part of a co-stimulatory pathway for T-cells that is
required for their full activation, which is induced by the
binding between CD80 (also known as B7-1) of APC cells
and CD28 (4) of T-cells in vivo. Following CD80 binding to
CD28, additional cell surface molecules are induced in both
APC cell and T-cells: CD86 (also known as B7-2) in APC
cells and the CTLA-4 receptor of T-cells. The T-cell response
from CD86 binding to CTLA-4 is inhibitory (negative
immune response), resulting in a balance with the “positive”
immune responses via binding between CD80 and CD28. To
maintain T-cells in a healthy condition requires a balance of
both “positive” and “negative” immune responses. Imbal-
anced bindings between CD28 and CD80 and between
CTLA4 and CD86 responses, both “over-active” and “un-
der-active” immune responses are pathological. There are
many autoimmune disease examples of “over-active” immune
responses.
Compounds such as FK506 (tacrolimus), which pene-
trates the cell membrane and intracellularly shuts down
particular pathways including signal 1, are currently being
investigated or used clinically as immunosuppressive agents
(5,6). While FK506 is a useful immuno-suppressive agent with
significant effects on T-cells for example, in inhibition of
transplantation rejection, it has severe side effects since it
shuts down many pathways in the cell. This indiscriminate
behavior also affects cells in other organs. For example, the
calcium ion pathway in cells is altered by FK506 due to its
effects on calcineurin, which may subsequently lead to the
disease of osteoporosis (lack of calcium in bone). Therefore,
recent efforts to find new immuno-suppressive drugs have
focused on cell membrane receptor’s antibodies (for example
anti-CD28 antibody, a non-mitogenic antibody being consid-
ered as outside T-cell blocker), which can efficiently block
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receptors but not affect other pathways inside cells. However,
using antibodies as drugs has many drawbacks including their
fragile nature (protease and peptidase digestion limits oral
availability and half-life) and poor stability (loss of 3-D
structure). Also, unlike small molecules, which mimic metab-
olites in the body, the large antibodies might induce other
immune system problems and therefore reduce their thera-
peutic utility.
In this study, the small organic compound, cynarin (see
Fig. 1), previously isolated from the north American herb
Echinacea purpurea with our recently established screening
method: After Flowing Through Immobilized Receptor
(AFTIR; see Fig. 2) (7) was further investigated. A detailed
understanding of the mode and types of binding of cynarin to
T-cell receptors is essential for further development of this
potentially new “mild” immuno-suppressive agent.
MATERIALS AND METHODS
Chemicals and Reagents. Silica gel 60 M (0.040–
0.063 mm) for chromatographic column packing was pur-
chased from Macherey-Nagel (Düren, Germany). Elution
solvents n-hexane, ethyl acetate and methanol (MeOH,
ChromAB grade, code no. 3041-68) were purchased from
Mallinckrodt Baker Inc. (Paris, KY). Silica gel 60 F254 thin
layer chromatography (TLC) 200 μm plates were purchased
from Merck (Darmstadt, Germany). Trifluoroacetic acid
(TFA 99% purity; Fluka, Switzerland) was used for eluent
pH adjustment. The cynarin reference standard (Batch No.
CHI20041218, 98.4%) was obtained from Fleton Reference
Substance Co., Ltd. (Chengdu, People’s Republic of China).
All other chemicals used were of analytical or chromato-
graphic grade.
Cell Lines, Media and Antibodies. Jurkat human acute T-
cell leukemia and Raji human B lymphocyte lines were
obtained from the Bioresource Collection and Research
Fig. 1. Structure of cynarin. Cynarin (1,3-dicaffeoylquinic acid)
structure was confirmed by mass spectroscopy and H1 NMR and
C13 NMR5.
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Fig. 2. AFTIR scheme. The compound cynarin was discovered in Echinacea extract by the AFTIR method. This schematic diagram shows the
immobilization of CD28 (extra-cellular part) in the chip. Many components from the extract of Echinacea purpurea, including cynarin, are
indicated by different symbols flowing across the immobilized CD28. Subsequently, only cynarin is bound to the specific binding site of CD28,
and other components are washed off the chip.
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Center (BCRC: HsinChu, Taiwan). RPMI-1640 medium was
purchased from HyClone (Logan, UT). Fetal bovine serum
(FBS) was purchased from Biological Industries (Haemek,
Israel). Penicillin–Streptomycin–Neomycin (PSN) Antibiotic
Mixture was purchased from Gibco BRL (Rockville, MD).
ELISA kits for human IL-2 were obtained from R&D
Systems (Minneapolis, MN). Anti-human CD28 antibody
and anti-human CD3 antibody were purchased from BioL-
egend (San Diego, CA). 3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) was purchased from
Sigma (St. Louis, MO). Water used in this study was de-
ionized and distilled. Anti-IL-2 mAb was supplied by R&D
Systems (Minneapolis, MN).
Purification of Cynarin. Cynarin was purified from
Echinacea purpurea extracts on a silica gel open column with
serial elution buffers of 1 L of 100% n-hexane, 1 L of 100%
ethyl acetate (EA), 3 L of 50% MeOH in EA, 3 L of 75%
MeOH in EA and 3 L of 100% MeOH. 200 mL of eluate with
each elution buffer was collected. After removal of solvent
and re-dissolution of eluted extract in water, the composition
of collected fractions was analyzed by HPLC under the same
condition as used for Echinacea crude extract. A typical
HPLC profile (absorbance at 254 nm) for cynarin fraction
and for Echinacea crude extract are shown in Fig. 8A, (a) and
(b), respectively. Composition of collected fractions was also
monitored by TLC using Silica gel 60 F254 plate in an EA:
isopropanol: H2O (8:5:3, v/v/v) mobile phase.
After HPLC analysis with DAD detector had determined
the cynarin fraction, the UV spectrum was recorded over the
whole elution duration (0–60 min.; see Fig. 8B). The fraction
marked by “T” shown in Fig. 8A, (a) was collected at a
retention time of 32.612 min, and the UV spectrum is shown in
Fig. 8B (black). For comparison, a UV spectrum of crude
extract is overlaid in Fig. 8B (blue). The results show that the
UV intensity of pure fraction including cynarin is much higher
than that of crude extract (note the different intensity scales).
The absorption peak shifted from 338 nm (crude extract) to
330 nm (cynarin pure fraction).
Stimulation of T-Cells. Jurkat T-cells were maintained in
a humidified atmosphere of 5% CO2/95% air at 37°C in
RPMI-1640 medium including penicillin, streptomycin and
10% heat-inactivated FBS. Two modes of T-cell stimulation
were used for the present experiments: Route 1 (R1): anti-
CD3 and anti-CD28, and Route 2 (R2): anti-CD3 and Raji B-
cells. (1) R1: signal 1 and signal 2 were stimulated via addition
of anti-CD3 and anti-CD28, respectively. Flat-bottom 96-well
plates were coated with 10 μg/mL of anti-CD3 for 24 h at 4°C.
Wells including anti-CD3 were then washed twice with
phosphate-buffered saline (PBS) to remove unbound anti-
CD3. Jurkat T-cells (200 μL, 2×106 cells/mL) with or without
cynarin (PBS buffer only; control group) were then added to
the wells. Cells were activated by anti-CD3 in wells for 15 min
(signal 1 stimulation). Consequently, anti-CD28 (1 μg/mL)
was then added into the wells (for signal 2 stimulation) for
24 h at 37°C. IL-2 release from stimulated T-cells (100 μL)
was then measured by enzyme-linked immunosorbent assay
(ELISA; see section below for detail). (2) R2: similar
procedures as shown for R1 above, 100 μL Jurkat T-cells
(2×106 cells/mL) with or without cynarin in PBS were pre-
incubated with anti-CD3 (50 ng/mL) for 15 min and then
100 μL Raji cells (2×106 cells/mL) were added to wells for
24 h at 37°C. IL-2 release from 100 μL of co-cultured T-cells
was again determined by ELISA.
IL-2 ELISA. A 96-well flat-bottom plate was coated
with anti-IL-2 mAb (100 μL at 4 μg/mL) in PBS (pH 7.3) at
room temperature overnight. The plate was washed three
times with 300 μL of PBS containing 0.05% Tween 20 (PBS-
T) and was incubated for more than 1 h with a blocking
solution containing 1% bovine serum albumin in PBS. After
plates were washed again with PBS-T, 100 μL of testing
sample (T-cell incubation medium) and 100 μL of biotinylated
anti-IL-2 detection antibodies (400 ng/mL) were added and
incubated for 2 h at room temperature. Finally, 100 μL of
streptavidin horseradish peroxidase (1/2,000 dilution of a
1.25 mg/mL solution) and 100 μL of substrate solution
containing H2O2 and tetramethylbenzidine (1:1 by volume)
were added for another 20 min in the dark at room
temperature. The reaction was terminated by the addition
of 50 μL stop solution (1 M H2SO4). The optical density of
each well at 450 nm was determined using a microplate
reader. The amount of IL-2 released from T-cells was
normalized by relative percentage (i.e. an IL-2 quantity,
1,200 pg/μl, is defined as 100%).
MTT Colorimetric Assay. The cytotoxicity of cynarin
treatment of T-cells was measured by MTT colorimetric assay.
100 μL Jurkat cells (5×105 cells/mL) were incubated with
different concentrations of cynarin for 24 h at 37°C. The cell
solution was then centrifuged at 200×g for 10 min and the
supernatant removed. 200 μL of MTT (0.5 mg/mL in culture
medium) was then added and the cell solution was incubated
again for 4 h at 37°C. 200 μL of DMSO lysis buffer was added
into the cell medium and the concentration of dissolved MTT
crystals was measured by plate reader (Dynatech, Chantilly,
VA) at 560 nm. The survival rate (%) was determined as
follows: OD560nm of tested sample (cells with cynarin)/
OD560nm of control (cells without cynarin)×100%.
Molecular Modeling and Docking. Cynarin (1,3-dicaf-
feoylquinic acid) was coordinated (PRODRG2) (8) based on
AutoDockTools (9), All hydrogen and flexible bonding of
cynarin shown in Fig. 1 were arranged to render Gasteiger
charge assignment. Crystal structure of CD28 was obtained
from Protein Data Bank (PDB/RCSB, 1YJD). The analysis
of automated docking including those parameters for global
docking was carried out (9): an initial population of random
individuals with a population size of 250 individuals was done
and a maximum number of 1×107 energy evaluations plus 100
docking runs were executed. The rest of the parameters were
set as default values. The grid maps were generated with 94×
126×110 points (grid-point spacing at 0.375 Å) by using
AutoGrid for CD28. To cluster the docked complex
conformations (CD28 with cynarin) according to their
docked locations, the center-of-mass for each of the
predicted cynarin conformations was computed. Using each
ligand conformation as a reference, the complex conformations
with distance less than 3 Å from its center-of-mass to the center-
of-mass of the reference were grouped into the same cluster.
The clustering is started with the reference of the conformation
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which had been surveyed by the lowest docked energy. A ligand
was assigned to a cluster once and was not used repeatedly. The
process was repeatedly boosted until all conformations were
stimulated in the same cluster. For local docking, the grid maps,
centered on the G-pocket binding site, were produced with 64×
60×60 points and a grid-point spacing at 0.375 Å. The docking
parameters were set as following: a population size of 250
individuals; a maximum number of 2.5×106 energy evaluations
and 50 docking runs. For both global and local dockings, the
clustering tolerance for the root-mean-square positional
deviation was set at 1.5 Å. The distance of center of mass
between ligand and protein was measured using VMD
program (10) and the results of docking were presented using
PYMOL software (11).
To identify the amino acids in CD28 which may interact
with cynarin through hydrogen bonding, the cluster consisting
of eleven CD28–cynarin conformations predicted with the
lowest docked energies (mean kilocalorie per mole) from
local docking procedure was closely examined.
RESULTS
Cynarin Inhibition of both Signal 1 and Signal 2-
Stimulated IL-2 Secretion. Jurkat T-cells (1×106 cells/mL)
were simultaneously activated via both signal 1 and signal 2
by (1) R1: anti-CD3 (signal 1) and anti-CD28 (signal 2) or (2)
R2: anti-CD3 (signal 1) and Raji cells (B-cells expressing cell
surface receptor, CD80, to activate signal 2 via binding with
CD28). When Jurkat T-cells are activated, they secrete
increased amounts of IL-2, while, if inhibition occurs, the
secretion of IL-2 by T-cells is reduced. The inhibition by
cynarin of activated Jurkat T-cells secretion of IL-2 was
investigated as a function of concentration (see Fig. 3). The
quantity of IL-2 was measured by ELISA and was normalized
to 100% at zero cynarin concentration. The IC50 of cynarin
was 823 μg/mL on R1 (filled square symbols) and 512 μg/mL
for R2 (open circles). MTT cell survival assay confirmed there
was no cytotoxic effect from cynarin on Jurkat T-cells within
the concentration used (up to 1,000 μg/mL; filled triangles).
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Fig. 3. IC50 on co-stimulated (signal 1+signal 2) of T-cell activation
and cytotoxicity of cynarin. The reductions of IL-2 production by T-
cells as a function of concentration of cynarin was plotted by route 1
(R1) (anti-CD3+anti-CD28; filled squares) and route 2 (R2) (anti-
CD3+B-cell; curve represented by open circles). There was little
cytotoxicity seen in T-cells at all concentrations of cynarin used, up to
1,000 μg/mL (MTT assay; represented by filled triangles). The
experiments were repeated four times and the average value and
error in average were shown.
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Fig. 4. Cynarin inhibition of T-cell signal 2-stimulated IL-2 production.
Signal 1 stimulation of T-cell immune response was initiated by the
Addition of anti-CD3 antibody and signal 2 was produced by the co-
culture of CD28-riched Jurkat cells with CD80-riched Raji cells. At the
fixed signal 2 (co-culture of Jurkat cells with Raji cells), the quantity of
IL-2 is gradually increased by the addition of anti-CD3 antibody (curve
(a)). With the addition of cynarin (500 μg/mL), the production of IL-2
was reduced as shown in curve (b). Without the addition of Raji cells,
the IL-2 was not produced (see curve(c)). The inset panels indicate the
production of IL-2 is lower at low concentration of anti-CD3 antibody.
The experiments were repeated four times and the average value and
error in average were shown.
103 104 105 106 107
-200
0
200
400
600
800
1000
1200
1400
1600
1800
(a)
(e)
(c)
(d)
IL
-2
 (p
g/m
l)
B-cells (cell/ml)
(b)
Fig. 5. Cynarin inhibition of T-cell signal 1-stimulated IL-2 produc-
tion. Jurkat T-cells (1×106 cells/mL) were co-cultured with different
cell densities of Raji cells (1×103 to 5×106 cells/mL). Anti-CD3
antibody was added at 100 ng/mL (curve (a) without cynarin and
curve (b) with 500 μg/mL cynarin) and at 50 ng/mL (curve (c) without
cynarin and curve (d) with 500 μg/mL cynarin). T-cell IL-2 production
without anti-CD3 antibody was shown in curve (e). The experiments
were repeated four times and the average value and error in average
were shown.
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Cynarin Inhibition of Signal 2-Stimulated IL-2 Secretion.
Activation of T-cells in nature requires both signal 1 and
signal 2. In this experiment, signal 2 was firstly initiated
through the co-culture of CD28-enriched Jurkat T-cells (1×
106 cells/mL) with CD80-enriched Raji B-cells (1×106 cells/
mL). Afterwards, signal 1-stimulation of T-cells was gradually
enhanced by the addition of anti-CD3 antibody. Without the
addition of cynarin, the IL-2 level increased as the
concentration of anti-CD3 antibody was increased (Fig. 4
(a)). With the addition of cynarin (500 μg/mL), the
production of IL-2 was reduced as shown in Fig. 4 (b).
Without the addition of Raji B-cells, there was no production
of IL-2 as the concentration of anti-CD3 antibody was
increased (see Fig. 4 (c)). Without the addition of anti-CD3
(A)
-11.5 -4.95
Fig. 6. G-pocket of CD28 appeared to be the most probable binding site for cynarin. Spatial locations of cynarin on CD28 were predicted with
100 runs of global docking analysis using AutoDock. A 3-D structure of CD28 with 100 superimposed cynarin predicted to be docked onto the
receptor. The yellow arrow indicates the location of G-pocket. The spheres indicate the center-of-mass of a cynarin molecule. The calculated
docked energies were presented with a red-to-blue gradient. Red indicated the lowest docked energy (i.e. −11.5 kcal/mol in this study and
suggesting the most probable conformation) while blue shows the highest (i.e. −4.95 kcal/mol). BA 3D scatter plot to show the binding location
on CD28 for each of the 100 predicted cynarin binding. The yellow arrow indicates the location of G-pocket. The majority of the predicted
cynarin bindings were clustered at the G-pocket of CD28 with relatively lower docked energies than the rest.
(A) (B)
Fig. 7. Computer simulation for the 3-D structure of a cynarin bound CD28. 3D structure of CD28–cynarin complex predicted with the lowest
docked energy was modeled by using PyMol9. A The interaction of cynarin with CD28 is shown by solid surface. The G-pocket of CD28 was
colored in blue. The bounded cynarin to CD28 was presented in sticks. B Computer autodock simulation of the blocking effect of cynarin
(middle part in red) between CD28 (lower part in blue; possible amino acids interacting with cynarin are indicated in yellow; the green shows the
loop of “MYPPPY”12) and CD80 (upper part in light blue; 3D structure of CD80 was cited from PDB/RCSB: 1DR9).
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antibody (see inset panel; zero concentration of anti-CD3
antibody), the quantity of IL-2 is about 30.5 pg/mL (where
the production of IL-2 is purely due to signal 2). Under this
condition, cynarin inhibits about 87.4% of signal 2-stimulated
IL-2 production (3.8 pg/mL of IL-2 is produced at zero
concentration of anti-CD3 antibody).
Cynarin did not Inhibit Signal 1-Stimulated IL-2 Secre-
tion. Activation of Jurkat T-cells requires the binding of anti-
CD3 antibody to TCR/CD3 (signal 1) and CD80 to CD28
(signal 2). Jurkat T-cells (1×106 cells/mL) were incubated
with different concentrations (1×103 to 5×106 cells/mL) of
Raji B-cells to see the effect of cynarin on signal 1 of T-cells in
the presence of two concentrations of anti-CD3 antibody
(Fig. 5 (a) and (b): 100 ng/mL anti-CD3, and Fig. 5 (c) and
(d): 50 ng/mL anti-CD3). In Fig. 5, curves (b) and (d) were
generated in the presence of 500 μg/mL cynarin, curves (a)
and (c) show the IL-2 production with no added cynarin. The
results showed that cynarin showed only minimal inhibition of
IL-2 production at different concentrations of anti-CD3
antibody. Curve (e) of Fig. 5 shows the absence of an
immune response when no anti-CD3 was added.
Binding between Cynarin and CD28. The binding site of
CD28 for cynarin was preliminarily predicted by grid
calculations on only CD28’s extra-cellular domain (PDB/
RCSB code 1YJD) by using AutoDock Tools (9). After-
wards, we further based on the method reported by Hetenyi
and Spoel (12) to analyze the global docking of CD28–
cynarin complex with at least 100 runs. The results show that
a group of 46 conformations bind intensely to a particular
area of CD28 and the rest of 54 conformations are distributed
over various other sites (mainly grouping into two sites) on
CD28 (see Fig. 6A). Further investigation was shown in
Fig. 6B indicating 100 binding complexes were intensely
grouped into three clusters. According to the relative spatial
distances between the center-of-mass of two putative bound
cynarin, 44 out of 46 cynarin molecules were bounded to the
so-called G-pocket area (13) of CD28. Based on these
observations, further binding details of cynarin molecule with
specific amino acids of CD28 (see Fig. 7A) were done using
“local docking” via Autodock program. The results prelimi-
narily indicate that about nine amino acid candidates were
possibly found to form hydrogen bonding with cynarin: i.e.
Lys2, His38, Ser43, Cys94, Asn106, Asn107, Lys109, Ser110
and Asn111. Among these candidates, His38, Asn107, Lys109,
and Ser110 are located in the G-pocket area of CD28. We
predict that the Serine at position 110 may be the most
possible to form hydrogen bond with cynarin in all the
simulated binding modes.
DISCUSSION
The method of AFTIR previously reported (7) has been
further demonstrated here to be a targetable and efficient
screening technique. Using AFTIR, we identified an immu-
nosuppressive compound, cynarin, which can block CD28
receptor of T-cells from binding with ligands such as CD80 of
B-cells. The computer simulation about the possible block
effect of cynarin between CD28 and CD80 was predicted and
shown in Fig. 7B.
We further investigated the binding of cynarin to the
CD28 of T-cell receptor to confirm its effectiveness as an
antagonist of the CD28/CD80 interaction and to ascertain its
potential as an immunosuppressive agent. Its high efficacy
blockade of the signal 2 pathway mediated through CD28 of
T-cells was confirmed. Cynarin binds more strongly to CD28
than CD80 does, and has no significant binding to other T-cell
receptors such as CD154, CD86 and CD40 (unpublished
results). This implies that cynarin may have few side effects in
the body and could be a good candidate for future therapeu-
tic drug development as an immunosuppressive agent, an
outside T-cell blocker.
The cynarin inhibition of T-cell IL-2 release is not strong,
since IC50 is about 512 μM for combined signal 1 and signal 2
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Fig. 8. HPLC profiling of cynarin fraction. Cynarin was purified from
Echinacea extracts by using silica gel open column as shown in A
curve (a). The absorption wavelength is at 254 nm. For comparison,
the crude extract HPLC profile of Echinacea was shown in A curve
(b) where T indicates the target to be isolated. The UV–VIS (220 to
400 nm) spectra of purified cynarin and crude extract at retention
time of 32.612 min are shown in B curves (black) and (blue),
respectively. Note the separate spectral intensities were indicated for
purified cynarin (curve in black) and crude extract (curve in blue).
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induced IL-2 release. When cynarin blocks signal 2 of T-cell
only (i.e., not blocking signal 1) there is about 87% reduction
of signal 2 of T-cell activation. Cynarin could be a mild
immunosuppressive compound with fewer side effects. In
vivo, immune responses occur in response to the presentation
of foreign antigens to T-cells. The T-cell activation is
moderated by the inhibition from CTLA-4 activation. The
activation of both positive responses (such as from CD80
binding to CD28) and negative responses produces a
balanced immune response. For patients with autoimmune
diseases, the balance is shifted towards more positive immune
responses causing an immune hyper-reaction. Thus, cynarin,
which blocks signal 2 only, could be used to suppress patients’
immune hyper-reaction. The mild immunosuppressive agent
like cynarin might be suitable for children who suffer
allergenic diseases. Furthermore, cynarin is one of main
components in the American herb, Echinacea purpurea (see
Fig. 8A, curve b). As shown in the section of cynarin
purification, the yield of this compound from Echinacea
would be sufficient in quantity and practically useful in the
future clinical applications: i.e. Cynarin has satisfied the first
requirement of “enough quantity” for later drug development
as a mild immunosuppressive agent.
Based on a preliminary computer simulation, we predict
that the cynarin binding site is located in the “G-pocket” of
CD28 and that when bound, it interacts with the nearby
“MYPPPY” Loop (14) (see Fig. 7B, green part). This is
probably an area that CD80 binds to. If CD80 is weakly
bounded to the CD28 with 1.11×10−6 M of the equilibrium
binding constant (Kd=kd/ka), cynarin has an ability to replace
CD80 to bind to the CD28 since its binding constant is about
1.7×10−7 M. The SPR binding experiments show further
evidence that cynarin can compete for the CD28 binding site
for CD80, since the binding capacity of CD80 is largely
reduced in the presence of cynarin. Further NMR
experiments need to be done to elucidate more detail of the
binding between CD28 and cynarin, and to describe the 3D
structure of the CD28/cynarin complex.
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